#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3301363	P	ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5		4,197	ALA3301361	small-molecule physicochemical format	AstraZeneca Deposited Data
2.	ALA3301364	P	ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM		1,763	ALA3301361	small-molecule physicochemical format	AstraZeneca Deposited Data
3.	ALA3301371	A	ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736	Rattus norvegicus	837	ALA3301361	cell-based format	AstraZeneca Deposited Data
4.	ALA3301372	A	ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.	Homo sapiens	408	ALA3301361	cell-based format	AstraZeneca Deposited Data
5.	ALA3889133	B	Biochemical Kinase Assay : Recombinant FGFR1 (2.5 nM), or FGFR4 (12 nM) was prepared as a mixture with substrate KKKSPGEYVNIEFG (SEQ ID NO:1) (20 μM, FGFR1 substrate); Poly [E,Y]4:1 (0.2 mg/ml, FGFR2,3,4 substrate)] in kinase reaction buffer (20 mM HEPES-HCl, pH 7.5, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 0.02% Brij35, 0.1 mM Na3VO4, 0.02 mg/ml BSA, 2 mM DTT, and 1% DMSO). Compound was added to the enzyme/substrate mixture using acoustic technology and pre-incubated for 0, 15, or 60 minutes at room temperature. After compound pre-incubation, 33P-γ-ATP was added at a final concentration of 10 μM to initiate kinase reactions. Reactions were incubated for 120 minutes at room temperature.		2	ALA3886956	single protein format	BindingDB Database
6.	ALA3889134	B	Biochemical Kinase Assay : Recombinant FGFR1 (2.5 nM), or FGFR4 (12 nM) was prepared as a mixture with substrate KKKSPGEYVNIEFG (SEQ ID NO:1) (20 μM, FGFR1 substrate); Poly [E,Y]4:1 (0.2 mg/ml, FGFR2,3,4 substrate)] in kinase reaction buffer (20 mM HEPES-HCl, pH 7.5, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 0.02% Brij35, 0.1 mM Na3VO4, 0.02 mg/ml BSA, 2 mM DTT, and 1% DMSO). Compound was added to the enzyme/substrate mixture using acoustic technology and pre-incubated for 0, 15, or 60 minutes at room temperature. After compound pre-incubation, 33P-γ-ATP was added at a final concentration of 10 μM to initiate kinase reactions. Reactions were incubated for 120 minutes at room temperature.	Homo sapiens	2	ALA3886956	single protein format	BindingDB Database
7.	ALA3998327	B	Inhibition of recombinant FGFR1 (unknown origin) using peptidic substrates in presence of ATP by Kinase-Glo luminescent kinase assay	Homo sapiens	1	ALA3997770	single protein format	Scientific Literature
8.	ALA3998328	B	Inhibition of recombinant FGFR2 (unknown origin) using peptidic substrates in presence of ATP by Kinase-Glo luminescent kinase assay	Homo sapiens	1	ALA3997770	single protein format	Scientific Literature
9.	ALA3998329	B	Inhibition of recombinant GST fused FGFR3 (unknown origin) using poly(EY) 4:1 as substrate in presence of [gamma-32P]ATP after 10 mins by scintillation counting method	Homo sapiens	1	ALA3997770	single protein format	Scientific Literature
10.	ALA3998330	B	Inhibition of recombinant FGFR4 (unknown origin) using peptidic substrates in presence of ATP by Kinase-Glo luminescent kinase assay	Homo sapiens	1	ALA3997770	single protein format	Scientific Literature
11.	ALA4013814	F	In vivo inhibition of FGFR2 in rat assessed as reduction in bFGF-induced CCL2 production at 10 mg/kg, po measured at 5 hrs post dose relative to control	Rattus norvegicus	1	ALA4011651	organism-based format	Scientific Literature
12.	ALA4013903	F	In vivo inhibition of FGFR2 in rat assessed as reduction in bFGF-induced CCL2 production at 10 mg/kg, po measured at 12 hrs post dose relative to control	Rattus norvegicus	2	ALA4011651	organism-based format	Scientific Literature
13.	ALA4013913	F	Anticancer activity in cholangiocarcinoma patient harboring FGFR2 translocation assessed as objective response rate	Homo sapiens	1	ALA4011651	assay format	Scientific Literature
14.	ALA4013914	F	Anticancer activity in metastatic urothelial cancer patient harboring FGFR3 mutant or translocation assessed as objective response rate	Homo sapiens	1	ALA4011651	assay format	Scientific Literature
15.	ALA4041200	B	Displacement of [3H]-cyclopamine from human wild-type SMO receptor expressed in HEK293T cell membranes by liquid scintillation spectrometry	Homo sapiens	14	ALA4038343	cell-based format	Scientific Literature
16.	ALA4041201	B	Displacement of [3H]-cyclopamine from SMO V404M mutant in gefitinib resistant human HCC827 cells by scintillation counting	Homo sapiens	10	ALA4038343	assay format	Scientific Literature
17.	ALA4041205	B	Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity at 2 uM by GLI1 luciferase reporter assay relative to control	Homo sapiens	8	ALA4038343	assay format	Scientific Literature
18.	ALA4041206	B	Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity at 60 uM by GLI1 luciferase reporter assay relative to control	Homo sapiens	8	ALA4038343	assay format	Scientific Literature
19.	ALA4041207	B	Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity at 2 to 60 uM in presence of SMO agonist SAG by GLI1 luciferase reporter assay	Homo sapiens	8	ALA4038343	assay format	Scientific Literature
20.	ALA4041213	B	Inhibition of SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in GLI1 activity by GLI1 luciferase reporter assay	Homo sapiens	8	ALA4038343	assay format	Scientific Literature